Gallagher, J., McCormack, D., Zhou, S., Ryan, F., Watson, C., McDonald, K., and Ledwidge, M. T. (2019) A systematic review of clinical prediction rules for the diagnosis of chronic heart failure. ESC Heart Failure, 6: 499--508. 10.1002/ehf2.12426.

Introduction {#ehf212426-sec-0004}
============

The diagnosis of chronic heart failure poses major challenges. Studies have shown that clinical assessment alone is grossly insufficient in the diagnosis of heart failure with only half of patients diagnosed having echocardiography evidence of heart failure.[1](#ehf212426-bib-0001){ref-type="ref"} However, access to echocardiography is often limited.[2](#ehf212426-bib-0002){ref-type="ref"} In the early 2000s, only a third of those with a clinical diagnosis of heart failure had echocardiography or further referral,[3](#ehf212426-bib-0003){ref-type="ref"} and this has not changed significantly in more recent times.[4](#ehf212426-bib-0004){ref-type="ref"}

Clinical prediction rules are defined as 'a clinical tool that quantifies the individual contributions that various components of the history, physical examination and basic laboratory results make towards the diagnosis, prognosis, or likely response to treatment in an individual patient'.[5](#ehf212426-bib-0005){ref-type="ref"} Such rules have been proposed in a number of areas as a solution to help guide physicians as to which patients may need referral. An adapted clinical prediction rule has been integrated into the National Institute for Health and Care Excellence guidelines in the UK on the diagnosis of chronic heart failure.[6](#ehf212426-bib-0006){ref-type="ref"}

The aim of this study was to undertake a systematic review of the literature to identify current clinical prediction rules used for the diagnosis of chronic heart failure in the community and to undertake a validation of these rules, where possible, in a novel cohort of patients referred to a rapid access heart failure diagnostic clinic by their general practitioner.

Methods {#ehf212426-sec-0005}
=======

The systematic review was undertaken according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses)[7](#ehf212426-bib-0007){ref-type="ref"} guidelines and the CHARMS checklist for systematic reviews of prediction models.[8](#ehf212426-bib-0008){ref-type="ref"}

Search strategy {#ehf212426-sec-0006}
---------------

The review question and design were framed using the CHARMS checklist for systematic reviews of prediction models[8](#ehf212426-bib-0008){ref-type="ref"} ([Appendix S1A](#ehf212426-supitem-0001){ref-type="supplementary-material"}). A systematic search strategy was then constructed for use in MEDLINE and Embase (details on the search syntax can be found in [Appendix S1B](#ehf212426-supitem-0001){ref-type="supplementary-material"}). In brief, a search string was developed to identify clinical prediction rules for the diagnosis of heart failure using terms including 'heart failure', 'cardiomyopathy' 'diagnosis', 'model', 'predict', 'decision', or 'score'. We searched for studies on the development, validation, and clinical impact of clinical prediction models for heart failure published between 1946 and Q4 2017. There was no language restriction.

Eligibility criteria {#ehf212426-sec-0007}
--------------------

Studies were eligible if they reported multivariable models for the diagnosis of heart failure in patients in the community.

Inclusion criteria for the systematic review were patient population: adult human patients,multivariable models relating to the diagnosis of heart failure,outcome measure: heart failure, andsetting of care: hospital outpatient or primary care (studies of clinical prediction rules conducted in non‐primary care settings were eligible for inclusion if they were relevant to primary care).

Exclusion criteria were studies that developed clinical prediction rules for patients with acute decompensated heart failure only,models that were designed to identify patients with acute heart failure, andstudies based on single predictors only (as they are prone to reporting overly optimistic findings owing to a number of methodological limitations).We used broad inclusion criteria to acknowledge variation in the same‐day diagnostic tests that are available across countries, with the understanding that not all countries will have access to the same services and that the role of primary care clinicians also differs internationally. Given the scope of the systematic review, we assessed all diagnostic prediction models retrieved by our search for their applicability to primary care. In particular, it must have been possible for diagnostic predictors or variables to be assessed in the community or at a general practitioner\'s surgery. Variables such as symptoms and signs, history taking, electrocardiogram (ECG), and blood tests are easily obtained, whereas items such as echocardiography or other advanced imaging are not.

Critical appraisal {#ehf212426-sec-0008}
------------------

We critically appraised studies using the CHARMS checklist list ([Appendix S1D--F](#ehf212426-supitem-0001){ref-type="supplementary-material"}).

Two reviewers (J. G. and D. M.) screened all titles and abstracts and made decisions regarding potential eligibility after full‐text review. In case of doubt, a third reviewer was consulted.

The reference lists of eligible studies as well as reviews relating to this subject were hand searched for identification of additional relevant publications. We also requested recognized experts to suggest other articles or sources.

For each included study, the following information was extracted on the basis of the CHARMS checklist by J. G.: source of data, participant characteristics, outcomes to be predicted, candidate predictors, sample size, handling of missing data, model development, model performance (discrimination and calibration), and model evaluation (internal or external validation) and results.

The methodological quality of each article was assessed using criteria based on a previous systematic review of clinical prediction rules in primary care based on modified McGinn criteria[5](#ehf212426-bib-0005){ref-type="ref"} in which the criterion concerning '100% follow‐up' was changed to 'adequate follow‐up' and was defined as ≥80% follow‐up of study participants.[5](#ehf212426-bib-0005){ref-type="ref"}, [9](#ehf212426-bib-0009){ref-type="ref"} There were eight criteria assessing internal and external validity for derivation studies, and for validation studies, there were five criteria ([Appendix S1C](#ehf212426-supitem-0001){ref-type="supplementary-material"}).

External validation {#ehf212426-sec-0009}
-------------------

Rules were validated in a dataset from the new heart failure diagnostic clinic in the St. Vincent\'s Healthcare Group, Dublin. Only those rules where the variables in the rule were available in the validation dataset were included**.** General practitioners referred suspected new‐onset cases to the rapid access clinic, which is part of the heart failure unit. Patients whose presentation indicated an acute onset were advised to go to the emergency department and were not included in this study. On attending the clinic, all patients underwent a systematic assessment including medical history and physical examination by a cardiology registrar and heart failure nurse specialist. Routine phlebotomy (haematology, renal profile, and natriuretic peptide) was also performed. Doppler echocardiography was performed in those with a B‐type natriuretic peptide (BNP) \> 100 pg/mL; in those with a BNP between 50 and 100 pg/mL already treated with diuretic and/or with a body mass index (BMI) \> 30; and in those with a BNP \< 50 pg/mL with further cardiovascular reason for echocardiographic assessment. The patient was then reviewed by a consultant cardiologist, and a decision was made to confirm or rule out the diagnosis of heart failure or, in equivocal situations, to send the patient for additional tests. Patients requiring additional tests were scheduled for review to confirm or rule out the diagnosis.

Heart failure was diagnosed on the basis of typical symptoms, with signs of fluid overload and/or an elevated BNP (\>100 or \>50 pg/mL with new diuretic use and/or elevated BMI), with Doppler echocardiographic evidence of systolic and/or diastolic dysfunction of the left ventricle or significant valvular disease.

Data analysis {#ehf212426-sec-0010}
-------------

It was possible to validate four rules in our novel cohort on the basis of the variables available in the cohort and those in the rules selected. For the four rules to be validated in our novel cohort, we retrospectively calculated the individual score or threshold of each included patient on the basis of models\' parameters. The area under the curve of the receiver operating characteristics curve, with 95% confidence intervals (CIs) were used to compare the overall discriminative ability of rules of the models. We also calculated the common diagnostic accuracy measures for the rules of the models, i.e. sensitivity, specificity, positive predictive values, and negative predictive values as well as their corresponding 95% CIs.

All calculations including statistical analysis were carried out using R language version 3.2.3.

Results {#ehf212426-sec-0011}
=======

A review of 5310 abstracts led to the identification of eight main models for the diagnosis of heart failure in the community and one updated model (*Table* [1](#ehf212426-tbl-0001){ref-type="table"}).[10](#ehf212426-bib-0010){ref-type="ref"}, [11](#ehf212426-bib-0011){ref-type="ref"}, [12](#ehf212426-bib-0012){ref-type="ref"}, [13](#ehf212426-bib-0013){ref-type="ref"}, [14](#ehf212426-bib-0014){ref-type="ref"}, [15](#ehf212426-bib-0015){ref-type="ref"}, [16](#ehf212426-bib-0016){ref-type="ref"}, [17](#ehf212426-bib-0017){ref-type="ref"}, [18](#ehf212426-bib-0018){ref-type="ref"} The search results are outlined in the PRISMA flow diagram (*Figure* [1](#ehf212426-fig-0001){ref-type="fig"}). One modification of a rule was identified.[18](#ehf212426-bib-0018){ref-type="ref"} One trial protocol for a clinical impact study of a clinical prediction rule was found.[19](#ehf212426-bib-0019){ref-type="ref"}

###### 

Summary of clinical prediction rule

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                         Author                                                                                                                                                                                                                                                                                                                                                             
  ---------------------- ------------------------------------ ------------------------------------ ----------------------------------------------------- ------------- ------------------------------------ ------------------------------------ ---------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------
  Year                   2007                                 2005                                 2000                                                  2000          2011                                 2011                                 2012                                           2015                                                                                        2016

  Stage of development   Derivation and external validation   Derivation and internal validation   Derivation                                            Derivation    Derivation and internal validation   Derivation and external validation   Derivation and external validation             Derivation and external validation                                                          Validate, update, and extend a rule for patients with COPD

  Clinical setting       26 general practices                 51 GP                                Single echocardiography clinic                        Three GPs     Geriatric outpatient clinic          HF outpatient clinic                 HF outpatient clinic                           GP                                                                                          30 general practices

  Design                 Prospective                          Cross‐sectional                      Prospective                                           Prospective   Prospective                          Prospective                          Prospective                                    Prospective                                                                                 Prospective

  Outcome                HF‐REF                               Heart failure                        HF‐REF                                                HF‐REF        Heart failure                        Heart failure                        Heart failure                                  Heart failure                                                                               Heart failure

  Patient age            10% age \> 65 years                  73 years                             65 years                                              71            82 years                             70.7 years                           71.5 years                                     71.6 years                                                                                  74.1 years

  Male                   40%                                  55.10%                               55%                                                   55%           62%                                  35.40%                               41%                                            53%                                                                                         45.5%

  Derivation cohort      458                                  405                                  466                                                   126           206                                  721                                  306                                            581                                                                                         

  Validation cohort      536                                  ---                                  ---                                                   ---           ---                                  407                                  936                                                                                                                                        585

  Model discrimination   0.88                                 0.76                                 0.83 for HF‐REF, 0.78 for ALVSD. 0.90 for EF \< 35%                 0.90 (0.86--0.94)                                                         0.88 in derivation, 0.84--0.93 in validation   0.82 clinical, 0.86 with clinical, ECG, and NT‐proBNP, 0.74 in external validation cohort   0.84 (range 0.80--0.85) of original rule\
                                                                                                                                                                                                                                                                                                                                                                                            0.88 (0.85--0.90) of updated rule

  Calibration            HL = 234.6                           ---                                  Not assessed                                          ---           HL and calibration plots             ---                                  Calibration plots                              HL \> 0.3 and calibration plots                                                             HL 0.02 poor calibration in original rule\
                                                                                                                                                                                                                                                                                                                                                                                            HL 0.56 good calibration in updated rule

  Comment                                                     COPD patients only                                                                                       Geriatric OPD referrals                                                                                                  Diabetes patients only                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALVSD, asymptomatic left ventricular systolic dysfunction; COPD, chronic obstructive pulmonary disorder; GP, general practitioner; HL, Hosmer‐Lemeshow test; OPD, outpatient department.

![PRISMA flow diagram.](EHF2-6-499-g001){#ehf212426-fig-0001}

Clinical settings for model development {#ehf212426-sec-0012}
---------------------------------------

Candidate variables varied widely from five to 36. Final predictors in the model varied from five to 11. Four rules used symptoms, eight rules used physical examination findings, five rules used ECG findings, and five rules used biomarker data (all relating to natriuretic peptides). The year of publication of the rules ranged from 2000 to 2016 and became more common in later years.

Heart failure subtypes {#ehf212426-sec-0013}
----------------------

Six rules addressed heart failure in general \[heart failure with reduced ejection fraction (HF‐REF) and heart failure with preserved ejection fraction (HF‐PEF)\], and three rules were for the prediction of HF‐REF only. No rule predicted HF‐PEF only. Three rules were developed for specific patient populations (diabetes, geriatric, and chronic obstructive pulmonary disorder).

Populations {#ehf212426-sec-0014}
-----------

Mean age was reported in eight rules; it varied from 65 to 82 years. One rule reported that only 10% of the patients were \>65 years. The proportion of male patients ranged from 35.4% to 55.1%. Four rules were derived from the general practice setting, two from referrals to a heart failure outpatient clinic, and one from an echocardiography unit. Six rules were derived from prospectively collected data.

### Year of publication {#ehf212426-sec-0015}

All the studies included in our literature review were published between 2000 and 2016.

### Stage of development {#ehf212426-sec-0016}

All clinical prediction articles involved derivation; two rules were solely derived, two had derivation and internal validation, and four had derivation and external validation. There were no clinical impact studies retrieved. However, one clinical prediction rule had a protocol for a clinical impact study published.[19](#ehf212426-bib-0019){ref-type="ref"}

### Clinical setting {#ehf212426-sec-0017}

The most common setting was general practice (five studies), followed by heart failure outpatient clinics (two studies), an echocardiography clinic (one study), and a geriatric outpatient clinic (one study).

### Variables/predictors {#ehf212426-sec-0018}

There was a wide range of both candidate and final variables used in the studies, which are represented in *Table* [2](#ehf212426-tbl-0002){ref-type="table"}.

###### 

Candidate and final predictors

                                  Fahey *et al*.   Rutten *et al*.   Yamamoto *et al*.   Nielsen *et al*.   Kelder *et al*.   Roalfe *et al*.   Boonman‐de Winter *et al*.   Oudejan *et al*.   Van Riet *et al*.
  ------------------------------- ---------------- ----------------- ------------------- ------------------ ----------------- ----------------- ---------------------------- ------------------ -------------------
  Age                                              ✔                                                        ✔✔                ✔                 ✔                            ✔✔                 ✔✔
  Gender                          ✔✔                                                                        ✔                 ✔✔                ✔                            ✔✔                 
  MI, CABG, or PCI                ✔✔                                 ✔✔                  ✔                  ✔✔                ✔✔                ✔                                               
  Dyspnoea, orthopnoea, and PND   ✔✔                                 ✔✔                                     ✔                 ✔                                              ✔✔                 
  Smoking status                                   ✔                                                        ✔                 ✔                 ✔                                               ✔
  IHD                                              ✔✔                                                                                           ✔                                               ✔✔
  Medication                      ✔                ✔                                                        ✔✔                ✔                 ✔                                               ✔
  Abnormal ECG                    ✔✔               ✔✔                ✔✔                  ✔✔                 ✔                 ✔                 ✔✔                           ✔                  ✔✔
  BNP/NT‐proBNP level                              ✔✔                                    ✔                  ✔✔                ✔✔                ✔✔                           ✔✔                 ✔✔
  Angina                          ✔                                                                                           ✔                 ✔                            ✔                  
  CCF                                                                ✔✔                  ✔                                                                                                      
  BMI/obesity                     ✔                ✔✔                                                       ✔                 ✔                                              ✔✔                 ✔✔
  Elevated JVP                    ✔✔               ✔                                                        ✔✔                                  ✔                            ✔                  ✔
  Displaced apex beat             ✔                ✔✔                                                       ✔✔                                                                                  ✔✔
  Abnormal chest X‐ray                                               ✔✔                                     ✔                                                                ✔                  
  Peripheral oedema                                ✔                                                        ✔                 ✔✔                ✔                                               ✔✔
  Asthma or COPD                                                                                            ✔                                   ✔                                               
  NT‐ANP                                                                                 ✔✔                                                                                                     
  Heart rate                                       ✔✔                                    ✔                  ✔✔                                                                                  ✔✔
  Blood pressure                  ✔                                                                         ✔                 ✔                 ✔                                               
  Wheeze                          ✔                                                                         ✔                                                                ✔✔                 
  heart murmur                    ✔                                                                         ✔✔                                                                                  ✔✔
  Hyperlipidaemia                 ✔                                                                                           ✔                                                                 
  Crepitations                                                                                                                ✔✔                ✔                                               
  TIA/stroke                                                                                                                  ✔                 ✔                                               
  Basal rales                                                                                               ✔✔                                                               ✔                  
  Irregularly irregular pulse                                                                               ✔✔                                                               ✔                  
  Diabetes                                                                                                  ✔                 ✔                                                                 
  Coronary revascularization      ✔                                                                                                                                                             
  Previous echocardiogram         ✔                                                                                                                                                             
  Cardiovascular co‐morbidity                      ✔                                                                                                                                            ✔
  Nocturia                                         ✔                                                        ✔                                                                ✔                  ✔
  C‐reactive protein                               ✔                                                        ✔                                                                                   ✔
  Haemoglobin                                                                                               ✔                                                                                   
  eGFR                                                                                                      ✔                                                                                   
  ALT \> 2 ULN                                                                                              ✔                                                                                   
  GGT \> 2 ULN                                                                                              ✔                                                                                   
  Abnormal spirometry                                                                                       ✔                                                                                   
  Alcohol consumption                                                                                                         ✔                                                                 
  Fatigue                                                                                                                     ✔                 ✔                                               
  PTCA                                                                                                                        ✔                 ✔                                               
  Peripheral vascular disease                                                                                                 ✔                                                                 
  Atrial fibrillation                                                                                                                           ✔                            ✔                  
  Loss of appetite                                                                                                                                                           ✔✔                 
  Digitalis                                                                                                                                                                  ✔                  
  Oral anticoagulants                                                                                                                                                        ✔                  

✔, candidate variables; ✔✔, final variables; ALT, alanine transaminase; ANP, atrial natriuretic peptide; BNP, B‐type naturitic peptide; CABG, coronary artery bypass graft; CCF, Chronic cardiac failure; COPD, chronic obstructive pulmonary disorder; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GGT, gamma‐glutamyl transpeptidase; IHD, ischaemic heart disease; JVP, jugular venous pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; PND, paroxmal nocturnal dyspnoea; PTCA, percutaneous transluminal coronary angioplasty; TIA, transient ischaemic attack; ULN, upper limit of normal.

### Bias {#ehf212426-sec-0019}

Factors affecting bias are outlined in [Appendix S1C](#ehf212426-supitem-0001){ref-type="supplementary-material"} and in the CHARMS data table ([Appendix S1D--F](#ehf212426-supitem-0001){ref-type="supplementary-material"}). A number of studies involved an unfavourable number of events per candidate variable, which can lead to overestimation of effect. In a number of studies, it was also not possible to blind assessors to the outcome, as this involved a consensus panel to reach the diagnosis of heart failure. The use of a consensus panel to establish the diagnosis of heart failure may have resulted in incorporation bias, by knowing the results of the diagnostic tests under study. However, there is general consensus that the resulting overestimation of the performance of some of the diagnostic items is outweighed by the gain in the accuracy of the outcome assessment by the panel.

### External validation {#ehf212426-sec-0020}

It was possible to validate four of the rules in our cohort. The demographics of the validation cohort are presented in *Table* [3](#ehf212426-tbl-0003){ref-type="table"}.

###### 

Demographics

                                                                                                                Not heart failure    Heart failure                             
  ------------------------------------------------------------------------------------------------------------- -------------------- -------------------- -------------------- --------------------
  *n*                                                                                                           448                  285                  116                  169
  Age[a](#ehf212426-note-0005){ref-type="fn"}                                                                   75.5 \[67.9:81.5\]   79.4 \[73.0:84.3\]   77.7 \[70.4:84.2\]   80.1 \[73.5:84.3\]
  Male[a](#ehf212426-note-0005){ref-type="fn"} ^,^ [b](#ehf212426-note-0006){ref-type="fn"}                     41.1%                50.5%                61.2%                43.2%
  Atrial fibrillation[a](#ehf212426-note-0005){ref-type="fn"} ^,^ [b](#ehf212426-note-0006){ref-type="fn"}      11.4%                53.7%                44.8%                59.8%
  Cancer                                                                                                        7.8%                 12.3%                14.7%                10.7%
  Cardiovascular disease[a](#ehf212426-note-0005){ref-type="fn"} ^,^ [b](#ehf212426-note-0006){ref-type="fn"}   16.7%                34%                  47.4%                24.9%
  Chronic renal failure[a](#ehf212426-note-0005){ref-type="fn"}                                                 1.6%                 5.6%                 8.6%                 3.6%
  COPD                                                                                                          14.1%                16.1%                19.8%                13.6%
  Diabetes                                                                                                      11.6%                16.5%                12.9%                18.9%
  Hypertension[b](#ehf212426-note-0006){ref-type="fn"}                                                          58.5%                61.8%                49.1%                70.4%
  Stroke/TIA                                                                                                    7.6%                 8.1%                 7.8%                 8.3%
  Valvular disease                                                                                              1.8%                 3.5%                 4.3%                 3%
  Baseline BMI (kg/m^2^)                                                                                        29.6 \[26.6:34.0\]   29.3 \[25.5:34.0\]   28.1 \[25.2:31.8\]   30.0 \[26.1:34.6\]
  Baseline SBP[b](#ehf212426-note-0006){ref-type="fn"} (mmHg)                                                   141 \[129:158\]      137 \[125:157\]      130 \[120:151\]      143 \[129:160\]
  Baseline DBP (mmHg)                                                                                           79 \[71:87\]         78 \[68:89\]         77 \[68:89\]         78 \[69:90\]
  Baseline creatinine[a](#ehf212426-note-0005){ref-type="fn"} (mg/dL)                                           1.10 \[0.92:1.32\]   1.25 \[1.05:1.60\]   1.30 \[1.09:1.73\]   1.19 \[1.04:1.47\]
  Primary aetiology                                                                                                                                                            
  Hypertensive                                                                                                                       43.5%                17.2%                61.5%
  Ischaemic                                                                                                                          35.8%                59.5%                19.5%
  Valvular                                                                                                                           9.5%                 6.0%                 11.8%
  Alcohol/drugs                                                                                                                      1.8%                 4.3%                 0%
  Idiopathic                                                                                                                         4.9%                 10.3%                1.2%
  Unknown                                                                                                                            4.6%                 2.6%                 5.9%

Bonferroni correction with *n* = 2 and *α* = 0.05. Cardiovascular disease includes ischaemic heart disease, peripheral arterial disease and abdominal aortic aneurysm.

COPD, chronic obstructive pulmonary disorder; DBP, diastolic blood pressure; SBP, systolic blood pressure; TIA, transient ischaemic attack.

Statistically significant for not heart failure vs. heart failure.

Statistically significant for reduced EF vs. preserved EF.

Results of external validation show that clinical prediction rules perform similarly in the novel cohort as in their original cohorts (*Table* [4](#ehf212426-tbl-0004){ref-type="table"}). However, their performance is similar to that of BNP alone in this cohort (*Figure* [2](#ehf212426-fig-0002){ref-type="fig"}).

###### 

Performance of clinical prediction rules in the novel cohort

  Author                                                       Subsample/threshold      AUC                     Sensitivity             Specificity             NPV                     PPV
  ------------------------------------------------------------ ------------------------ ----------------------- ----------------------- ----------------------- ----------------------- -----------------------
  BNP alone                                                    BNP                      85.9% \[83.3--88.6%\]   80.1% \[75.6--84.7%\]   80.2% \[76.5--84.0%\]   85.4% \[82.0--88.8%\]   73.7% \[68.9--78.5%\]
  Roalfe[16](#ehf212426-bib-0016){ref-type="ref"}              MICE                     64.9% \[61.0--68.8%\]   61.8% \[56.3--67.2%\]   59.7% \[55.2--64.2%\]   69.8% \[65.3--74.4%\]   50.8% \[45.7--55.9%\]
  Roalfe                                                       MICE and ECG             70.4% \[66.5--74.3%\]   64.3% \[58.570.1%\]     63.8% \[59.1--68.5%\]   73.4% \[68.8--78.0%\]   53.5% \[48.059.0%\]
  Roalfe                                                       MICE and BNP             86.6% \[84.1--89.2%\]   79.8% \[75.2--84.4%\]   79.8% \[76.0--83.6%\]   85.1% \[81.6--88.6%\]   73.1% \[68.3--78.0%\]
  Roalfe                                                       MICE and ECG and BNP     88.6% \[86.1--91.1%\]   81.5% \[76.7--86.2%\]   81.3% \[77.4--85.2%\]   86.7% \[83.2--90.2%\]   74.6% \[69.5--79.6%\]
  Fahey[10](#ehf212426-bib-0010){ref-type="ref"}               MIJO                     65.1% \[61.2--68.9%\]   66.0% \[60.7--71.3%\]   54.8% \[50.3--59.4%\]   70.5% \[65.8--75.3%\]   49.6% \[44.8--54.5%\]
  Fahey                                                        MIJO and ECG             69.4% \[65.5--73.4%\]   61.2% \[55.3--67.1%\]   65.3% \[60.6--69.9%\]   72.2% \[67.6--76.8%\]   53.3% \[47.7--58.9%\]
  Fahey                                                        MIJO and BNP             86.9% \[84.3--89.4%\]   79.5% \[74.9--84.1%\]   79.5% \[75.7--83.3%\]   84.9% \[81.4--88.4%\]   72.8% \[68.0--77.7%\]
  Fahey                                                        MIJO and ECG and BNP     88.7% \[86.2--91.2%\]   81.5% \[76.7--86.2%\]   81.6% \[77.7--85.4%\]   86.7% \[83.2--90.2%\]   74.8% \[69.8--79.9%\]
  Boonman‐de Winter[17](#ehf212426-bib-0017){ref-type="ref"}   Clinical score           64.1% \[60.8--67.4%\]   71.6% \[67.7--75.6%\]   49.8% \[45.7--53.9%\]   66.7% \[62.2--71.2%\]   55.6% \[51.8--59.6%\]
  Boonman‐de Winter                                            Clinical score and BNP                                                                                                   
  Yamamoto[12](#ehf212426-bib-0012){ref-type="ref"}            Clinical score           60.7% \[56.5--64.9%\]   70.8% \[65.5--76.1%\]   45.7% \[40.9--50.5%\]   69.4% \[63.9--74.9%\]   47.4% \[42.6--52.2%\]
  Yamamoto                                                     Any 1--4 and BNP         65.0% \[62.3--67.7%\]   58.2% \[54.2--62.2%\]   71.8% \[68.0--75.5%\]   62.3% \[58.6--66.1%\]   68.1% \[64.0--72.2%\]

AUC, area under the curve; MICE, male, infarction, crepitations, oedema; NPV, negative predictive value; PPV, positive predictive value.

![Calibration plots for BNP alone (A), MICE[16](#ehf212426-bib-0016){ref-type="ref"} rule with BNP (B), and MIJO[10](#ehf212426-bib-0010){ref-type="ref"} rule with BNP (C). BNP, B‐type natriuretic peptide.](EHF2-6-499-g002){#ehf212426-fig-0002}

Discussion {#ehf212426-sec-0021}
==========

This study sought to review the literature for clinical prediction rules for the diagnosis of patients with chronic heart failure in the community and validate them, where possible, in a novel cohort.

Eight previously developed rules for the diagnosis of chronic heart failure in the community and one adaptation of a rule were identified. Four were externally validated, and one is undergoing a clinical impact study. In those studies that estimated the effect of natriuretic peptide on the performance of the clinical prediction rule, and in our own validation study, this biomarker performed as well as, and indeed better than in some cases, the proposed clinical prediction rules. It may be that clinical prediction rules based on symptoms and signs may not add to the diagnostic process and a natriuretic peptide‐based approach in those patients in whom the general practitioner considers heart failure as a diagnosis may be as useful. Although there are concerns about overestimation of single‐marker models, a biomarker‐based approach should be investigated in comparison with the use of clinical prediction rules based on symptoms and clinical signs only for the diagnosis of heart failure in the community in a clinical impact study. Also the use of multimarker panels should be researched further. A paper from the REFER study supports this as natriuretic peptide testing alone performed as well as the validated clinical prediction rule in determining which patients presenting with symptoms went on to have a diagnosis of heart failure. It was also noted that the current N‐terminal proBNP (NT‐proBNP) cut‐off level of 400 pg/mL used in the UK is too high and means that one in five patients with heart failure may not be appropriately referred for further investigation and diagnosis.[20](#ehf212426-bib-0020){ref-type="ref"}

This systematic review of clinical prediction rules in the diagnosis of chronic heart failure in the community used an extensive literature search and structured critical appraisal of the models using the guidance of the CHARMS checklist of the Cochrane collaboration. The validation cohort in this study is large compared with that used for the derivation of these rules. However, the validation study was conducted in Ireland in which general practitioners are health care gatekeepers. Therefore, the results may be less generalizable to health care settings where primary care does not play such a role. We were unable to validate four of the rules as some variables were not available. However, the missing variables such as cardiothoracic ratio and biomarkers such as adrenomedullin or atrial natriuretic peptide are not part of current guidelines and not widely used on a clinical basis. Also, following guidelines on validation of clinical prediction models, we wanted to refrain from simplification of these models by excluding those predictors that were not available and then re‐fitting new model on our data, as this would lead to the development of even more new models. Simply omitting these missing predictors from the full models without further re‐fitting would lead to structural underestimation of the risk and poor clinical performance. Therefore, validation of these diagnostic prediction models was not undertaken. Because BNP was used in some cases to identify those who may not require echocardiography, this may have led to an overestimation of its predictive ability and highlights also the difficulty with the use of single markers in diagnostic prediction. It highlights another feature of clinical prediction rules in that often features associated with the diagnosis are part of the clinical prediction rule, and therefore, caution should be exercised when using features of a clinical prediction rule on their own rather than as part of the rule. However, the results here are similar to those of a recently published paper highlighting that NT‐proBNP testing alone performed as well as the MICE (male, infarction, crepitations, oedema) rule in determining which patients presenting with possible heart failure symptoms went on to have a diagnosis of heart failure.[20](#ehf212426-bib-0020){ref-type="ref"}

Other systematic reviews on clinical prediction rules in heart failure have focused on risk prediction, rehospitalization, and diagnosis of acute heart failure.[21](#ehf212426-bib-0021){ref-type="ref"}, [22](#ehf212426-bib-0022){ref-type="ref"} These studies have also shown a lack of impact analysis, and this has been noted in other areas of cardiovascular disease also.[23](#ehf212426-bib-0023){ref-type="ref"} This lack of clinical application of these rules makes it difficult to determine the impact that they have on patient care, physician behaviour, and health care costs. This review clearly indicates that many of the studies are similar in design as corresponding models often include similar predictors and include similar patient populations. Therefore, researchers are often repeating the same process and mostly introduce implicit knowledge when developing a prediction model from scratch. Over the past few decades, statistical methods for building prediction models using established knowledge have substantially improved, and these can be achieved by refining, updating, extending, and even combining the most promising existing models for diagnosis of heart failure in the general population, as was undertaken in the most recent model.[18](#ehf212426-bib-0018){ref-type="ref"}

Ideally, systematic reviews also guide evidence informed health decision making, in this case leading to recommendations on which models to advocate or even use in guidelines for the diagnosis of heart failure. Given the lack of clinical impact studies, we believe it is impossible to recommend which specific model or models should be used in which setting or location. Similarly, the adaptation of models for use in guidelines[6](#ehf212426-bib-0006){ref-type="ref"} without validation may lead to diagnostic inaccuracy and should be discouraged.

The validity, and thus potential impact, of models for the diagnosis of heart failure could substantially be improved by making better use of existing evidence, rather than starting from scratch to develop yet another model and undertaking clinical impact studies to determine the utility of these models. The most suitable and promising models for a particular targeted population should be identified and subsequently be validated (and if necessary tailored to the situation at hand), allowing for head‐to‐head comparisons such as previously performed for prediction models for the development of type 2 diabetes.[24](#ehf212426-bib-0024){ref-type="ref"}

Conclusions {#ehf212426-sec-0022}
===========

The use of clinical prediction rules in chronic heart failure may help improve access to diagnostics for those most likely to have significant findings. However, the rules identified during this review require further validation and clinical impact studies before integration into guidelines. In particular, the approach of using a clinical prediction rule compared with natriuretic peptide testing or use of a multimarker panel as a rule‐out test in people presenting with symptoms of chronic heart failure should be evaluated.
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